Nanopath Inc., a Cambridge, Mass.-based point-of-care diagnostics company enabling high-quality molecular testing in minutes, received $4m in federal funding.
The company was awarded:
- a $3m grant from the National Institutes of Health (NIH) and
- a $1m grant from the National Science Foundation (NSF).
Both grants were awarded through the Small Business Innovation Research (SBIR) Program, a competitive program designed to stimulate technological innovations developed by small businesses. These grants bring the company’s total funding to over $15m.
The funding will support the development of its point-of-care diagnostic platform for women’s health.
Led by CEO Amogha Tadimety, and President, and CTO, Alison Burklund, Ph.D., co-founder, Nanopath is dedicated to improving health equity worldwide, starting with women’s health via a proprietary molecular diagnostic testing platform. The company has developed advanced prototypes of both its disposable test cartridge and benchtop readout instrument and is actively developing its pipeline of test offerings through clinical collaborations with preeminent hospitals in New England.
